Advertisement
U.S. markets open in 5 hours 45 minutes

iBio, Inc. (IBIO)

NYSE American - NYSE American Delayed Price. Currency in USD
1.05000.0000 (0.00%)
At close: 04:00PM EDT
1.0792 +0.03 (+2.78%)
After hours: 06:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close1.0500
Open1.0700
Bid0.0000 x 1200
Ask0.0000 x 4000
Day's Range1.0500 - 1.1300
52 Week Range1.0200 - 52.0000
Volume93,070
Avg. Volume105,941
Market Cap3.658M
Beta (5Y Monthly)-3.80
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • iBio, Inc.
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more
  • InvestorPlace

    3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever

    Even the most conservative investor hopes to find that one stock that can make them millions. That’s why they look at the biotech sector. One “home run” drug or therapeutic to enter the market can send a stock soaring along with an investor’s portfolio. The problem is that many of these long-term biotech stock investments never pan out. On the other hand, many potentially high return biotech stocks are excellent buy and hold candidates. Some of these companies, particularly the small-cap stocks